ML277
ML277 物理性質
- 比重(密度) :
- 1.341±0.06 g/cm3(Predicted)
- 貯蔵温度 :
- 2-8°C
- 溶解性:
- DMSO: 5 mg/ml
- 外見 :
- 粉
- 酸解離定数(Pka):
- 8.37±0.70(Predicted)
- 色:
- 白からベージュ
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TOC4777 |
ML 277 |
1401242-74-7 |
10mg |
￥79000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TOC4777 |
ML 277 |
1401242-74-7 |
50mg |
￥332000 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
SML0524 |
≥98% (HPLC)
ML277 ≥98% (HPLC) |
1401242-74-7 |
5mg |
￥25600 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
SML0524 |
≥98% (HPLC)
ML277 ≥98% (HPLC) |
1401242-74-7 |
25mg |
￥76500 |
2024-03-01 |
購入 |
ML277 化学特性,用途語,生産方法
説明
Potassium (K
+) channels are categorized by their mode of activation and the number of transmembrane segments. The voltage-
gated six-
transmembrane K
+ channels include KCNQ1, first recognized for its role in cardiac function and subsequently in hearing, gastrointestinal chloride secretion, and other processes. ML-
277 is a potent activator of KCNQ1 channels (EC
50 = 260 nM). The EC
50 value of this compound at the related channels KCNQ2, KCNQ4, and hERG exceeds 30 μM. ML-
277 potentiates both homomultimeric KCNQ1 channels and unsaturated heteromultimeric (KCNQ1/KCNE1) channels in model cardiomyocytes and augments delayed rectifier K
+ current in cultured human cardiomyocytes.
使用
ML277 has been used as the KCNQ1 activator to treat?cells in lung metastasis?assay.
Biochem/physiol Actions
ML277 is a potent activator of KCNQ1 (Kv7.1) channels with >100-fold selectivity versus KCNQ2 and KCNQ4 and no activity against the hERG potassium channel up to 30 μM. KCNQ1 is a voltage-gated potassium channel required for repolarization phase of the cardiac action potential. Mutations in the KCNQ1 gene are associated with long QT syndrome (LQTS), a disorder in which the heart muscles take longer than normal to recover after each heart beat and can lead to dangerous arrhythmias such as atrial fibrillation. Activators of KCNQ1 channels could have potential use in treatments of LQTS. ML277 is the first selective and potent activator found, with an EC50 of 260 nM.
ML277 上流と下流の製品情報
原材料
準備製品
ML277 生産企業
Global( 118)Suppliers
1401242-74-7()キーワード:
(2R)-N-tert-ブチル-2-[4-tert-ブチルフェニル(2-フリルカルボニル)アミノ]-2-(3-ピリジル)アセトアミド
4-[3-フェニル-5-(4-メトキシフェニル)-4,5-ジヒドロ-1H-ピラゾール-1-イル]ベンゼンスルホンアミド
ML221
2-(4-メチルベンゼンスルホンアミド)-N-(4-フェニル-1,3-チアゾール-2-イル)-4-(トリフルオロメチル)ベンズアミド
1-(3,4-ジフルオロフェニル)-3-(1-フェニル-3-メチル-1H-ピラゾール-5-イル)尿素
ML-7塩酸塩
N-[4-({5-[3-(フラン-2-イルメチル)-4-オキソ-1,2-ジヒドロキナゾリン-2-イル]-2-メトキシフェニル}メトキシ)-3,5-ジメチルフェニル]アセトアミド
N-[4-(1H-1,2,3-トリアゾール-1-イル)ベンジル]-2-(2-イソプロピルフェニル)-5-メチル-4-ピリミジンアミン
1-[(5-クロロ-1-ナフタレニル)スルホニル]ヘキサヒドロ-1H-1,4-ジアゼピン·塩酸塩
4β-(4-イミノ-7-ベンジル-5,6-ジフェニル-3,4-ジヒドロ-7H-ピロロ[2,3-d]ピリミジン-3-イル)シクロヘキサン-1β-オール
ML161
スルファミン酸[(1R)-2β-ヒドロキシ-4α-[5-[1-(3-ブロモベンジル)-1H-ピラゾール-3-イルカルボニル]-4-ピリミジニルアミノ]シクロペンタン-1α-イル]メチル
- 1401242-74-7
- VU0458298-2, VU0458298-3
- ML277
- (2R)-N-[4-(4-Methoxyphenyl)-1,3-thiazol-2-yl]-1-(4-methylphenyl)sulfonylpiperidine-2-carboxamide
- (R)-N-(4-(4-Methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide
- CID-53347902
- ML277;ML 277; ML-277
- (2R)-N-[4-(4-Methoxyphenyl)-1,3-thiazol-2-yl]-1-[(4-methylphenyl) sulfonyl]-2-piperidinecarboxamide
- (2R)-N-[4-(4-Methoxyphenyl)-2-thiazolyl]-1-[(4-methylphenyl)sulfonyl]-2-piperidinecarboxamide
- ML-277;ML 277;CID-53347902;CID53347902;CID 53347902
- 2-Piperidinecarboxamide, N-[4-(4-methoxyphenyl)-2-thiazolyl]-1-[(4-methylphenyl)sulfonyl]-, (2R)-
- N-[4-(4-methoxy-phenyl)-thiazol-2-]-1-[1-(4-Methylbenzenesulfonyl) pip- eridine -2-] formamide
- ML-277|||CID-53347902
- ML277, 10 mM in DMSO